Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) reached a new 52-week low during trading on Tuesday. The stock traded as low as GBX 29 and last traded at GBX 30.50, with a volume of 53,958 shares changing hands. The stock had previously closed at GBX 31.50.
Faron Pharmaceuticals Oy Trading Down 3.2%
The business has a fifty day simple moving average of GBX 35.89 and a 200 day simple moving average of GBX 53.80. The company has a debt-to-equity ratio of 154.15, a quick ratio of 1.09 and a current ratio of 2.40. The stock has a market capitalization of £61.88 million, a price-to-earnings ratio of -2.65 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
- Republic Services Has the Momentum, But Waste Management Has Another Advantage
- Alphabet’s Golden Dome Talks Could Open a New Market, But How Much Is at Stake?
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
